31 slides from Advanced Enzyme Technologies's earnings presentation, May 13, 2025
Slide 1: Exchange filing cover letter
May 13, 2025 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Subject: Earnings Presentation Ref: ISIN: INE837H01020 Dea
Slide 2: Advanced Enzyme Technologies Limited Earnings Presentation May 2025
Advanced Enzyme Technologies Limited Earnings Presentation | May 2025
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,” “expect,” “an
Slide 4: Result Summary Business Performance
1 2 3 Result Business Geographical Summary Performance Performance Page: 04 Page: 07 Page: 11 4 5 6 7 Financial Unique Focus Area Shareholders’ Statements Investment Case Going Ahead Information Page: 12 Page: 23 Page: 28 Page: 29 Earnings Presentation | May 2025 3
Slide 5: Results Summary – FY25 (Consolidated) Y-o-Y
Results Summary – FY25 (Consolidated) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 6,239 6,369 2,045 1,370 1,944 1,340 02% 05% 02% FY24 FY25 FY24 FY25 FY24 FY25 Revenue grew by 2 % on y-o-y basis to EBITDA declined by 5% at ₹ 1,944 million in PAT de-grew by 5% at ₹ 1,340 million in EBITDA margin an
Slide 6: Results Summary – Q4 FY25 (Consolidated) Y-o-Y
Results Summary – Q4 FY25 (Consolidated) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,672 554 1,578 456 06% 18% 11% 299 267 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Revenue grew by 6% on y-o-y basis to EBITDA de-grew by 18% to ₹ 456 million in Q4 PAT decreased to ₹ 267 million in Q4 FY25 E
Slide 7: Results Summary – Q4 FY25 (Consolidated) Q-o-Q
Results Summary – Q4 FY25 (Consolidated) Q-o-Q Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,691 1,672 553 389 456 01% 17% 31% 267 Q3 FY25 Q4 FY25 Q3 FY25 Q4 FY25 Q3 FY25 Q4 FY25 Revenue declined by 1% on q-o-q basis to ₹ 1,672 million in Q4 EBITDA de-grew by 17% to ₹ 456 million in Q4 FY25 as PAT decre
Slide 8: Human Nutrition
Human Nutrition (₹ in Million) 1,059 1,107 Commentary: 1,024 1,012 1,018 1,031 994 992 • The human nutrition segment contributed 877 around 62% during the quarter to the total revenue from operations • This segment grew by 1% during the quarter from ₹ 1,024 million in Q4 FY24 to ₹ 1,031 million in Q
Slide 9: Animal Nutrition
Animal Nutrition (₹ in Million) Commentary: 206 209 197 • The animal nutrition segment contributed 185 181 173 172 around 12% during the quarter to the total 158 162 revenue from operations • This segment grew by 13% during the quarter from ₹ 185 million in Q4 FY24 to ₹ 209 million in Q4 FY25 wherea
Slide 10: Industrial Bio-processing
Industrial Bio-processing (₹ in Million) Commentary: 321 • The Industrial Bio-Processing segment contributed about 17% during the quarter to the total revenue from 278 258 operations 243 251 236 • This segment grew by 8% on y-o-y basis to ₹ 278 million 224 in Q4 FY25 from ₹ 258 million in Q4 FY24 wh
Slide 11: Specialized Manufacturing
Specialized Manufacturing (₹ in Million) Commentary: 154 154 • This segment contributed about 9% during the quarter to the total revenue from operations 120 which was 7% during the same quarter last 113 111 110 103 104 year 97 • This segment grew by 39% on y-o-y basis to ₹ 154 million in Q4 FY25, an
Slide 12: Geographical performance
Geographical performance (₹ in Million) Rest of the India Americas Europe Asia* World 42% 39% 06% 11% 02% Q4 FY25 -09% +22% -25% +48% +116% Q4 FY25 704 Q4 FY25 646 Q4 FY25 102 Q4 FY25 181 Q4 FY25 40 Q4 FY24 774 Q4 FY24 528 Q4 FY24 135 Q4 FY24 122 Q4 FY24 18 46% 37% 05% 09% 03% FY25 -06% +13% -16% +2
Slide 13: Profit & Loss (Consolidated) – Q4 & FY25
Profit & Loss (Consolidated) – Q4 & FY25 (₹ in Million) Q4 FY25 Q3 FY25 Q4FY24 Y-o-Y Q-o-Q FY25 FY24 Particulars Y-o-Y (%) Audited Un-Audited Audited (%) (%) Audited Audited Income from Operations 1,672 1,691 1,578 6% -1% 6,369 6,239 2% Expenses 1,317 1,228 1,118 18% 7% 4,790 4,547 5% Profit from Op
Slide 14: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) (₹ in Million) FY25 FY24 FY23 Particulars Audited Audited Audited Assets Property, plant and equipment 2,929 2,765 2,732 Capital work-in-progress 217 411 215 Intangible assets 523 479 550 Goodwill 3,334 3,253 3,209 Other non-current assets 411 350 291 Current assets 8,79
Slide 15: Strong Financial Performance – FY25
Strong Financial Performance – FY25 (₹ in Million) Revenue from Operations EBIDTA & EBIDTA Margin (%) 6,239 6,369 2,500 46% 50% 5,294 5,406 38% 45% 5,018 33% 2,000 40% 29% 31% 35% 1,500 30% 25% 1,000 20% 15% 500 10% 2,316 2,014 1,564 2,045 1,944 5% 0 0% FY 21 FY 22 FY 23 FY 24 FY 25 FY 21 FY 22 FY 2
Slide 16: Strong Financial Performance – FY25
Strong Financial Performance – FY25 Net Working Capital (Days) Net Worth (₹ mn) 146 14,209 132 135 135 13,241 120 12,351 10,886 9,709 FY 21 FY 22 FY 23 FY 24 FY 25 FY 21 FY 22 FY 23 FY 24 FY 25 ROE (%) & ROCE (%) Net Debt to Equity (x) 21.94% 0.02 0.02 0.02 15.93% 13.03% 16.71% 10.34% 11.31% 0.01 0.
Slide 17: Annexure
Annexure
Slide 18: Company Overview
Company Overview Advanced Enzymes is a research driven company with global Probiotics are live microorganisms, when administered in sufficient amount, leadership in the manufacturing of enzymes and probiotics. confer health benefits to human and animals. Probiotics have now become We are committed t
Slide 19: A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star 9 68+ 400+ 700+ Manufacturing Units Enzymes Proprietary Customers India – 8 | USA - 1 7 & Probiotics Products Worldwide R&D Units India – 5 | USA – 1 | Germany –1 45+ 750+ 17* 1st Countries Worldwide Presence Employees Patents Indian Enzyme
Slide 20: Brief History and Evolution
Brief History and Evolution • Equity investment • 4 food enzymes got by Kotak Private approved as a Equity processing aid with • Received approval for 2 • Takeover of Food Safety Standard • Received NIH grant for food enzyme dossiers Advanced Authority of India ImmunoSEB and from EFSA Supplementary
Slide 21: Board of Directors
Board of Directors Mr. Vasant Rathi Mr. Mukund M. Kabra Mr. Pramod Kasat Promoter Chairman and Non-Executive Director Whole-time Director Independent Director Ms. Rasika Rathi Mr. Vinod Jajoo Mr. Sunny Sharma Non-Executive Director Independent Director Non-Executive Director Ms. Rajshree Patel Mr. N
Slide 22: Management Team
Management Team Group Chief Financial Officer Vice President / Market & Business CFO & COO - Advanced Enzymes, USA Managing Director /Head Of Business Development Development - evoxx Technologies, Germany General Counsel / Vice President Managing Director /Head Of Research and Company Secretary & He
Slide 23: How Big is the Opportunity?
How Big is the Opportunity? Global Enzymes Market Global Probiotics Market Grow at a $6Bn 8% Grow at a CAGR 7.75% CAGR 6% $11.3Bn CY 2023-28 till 2030 $7Bn $923Mn 11% $57Bn $400Mn 81% $70Bn $1.85Bn $3.57Bn $250Mn $500Mn $800Mn Animal Feed Dietary Supplements Functional Food & Beverages $1.01Bn $1.02
Slide 24: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? Specialized Business with High Entry Barriers Strong Research & Development Capabilities Integrated Player with Presence Across the Enzyme Value Chain Inherent Diversification in the Business Model Significant Focus on International Markets & Brand Building
Slide 25: Integrated Player with Presence Across the Enzyme Value Chain
Integrated Player with Presence Across the Enzyme Value Chain Research & Development Manufacturing Marketing & Distribution Earnings Presentation | May 2025 24
Slide 26: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? Addressable market for AETL over next 5 AETL’s Current Share of Revenue Focus Area Opportunity Size years** FY25 FY24 Human Nutrition $ 400 mn $ 200 mn $ 41.6 mn, 55% $ 43.5 mn, 58% Bio-Catalysis $ 60 mn $ 30 mn* $ 2.1 mn, 3% $ 3.3 mn, 4% Baking $ 300 mn $ 30 m
Slide 27: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers Technocrat Global Promoters Competitiveness Amongst the Lowest Cost Cumulative experience of 7+ decades Manufacturers in the World in the global enzyme industry (Benchmarked both in terms of Capex & Opex) Sustained Research Diverse Product Range & Develo
Slide 28: Future Growth Drivers
Future Growth Drivers Continued Broaden & Deepen Inorganic Investment in R&D Geographical Presence Expansion o Acquisition of Key Technologies, Competencies & o Identify Product gaps and Develop new Enzymes, o Increased focus on high return applications where Skill-sets which Enable Consolidation an
Slide 29: Focus Areas Going Ahead
Focus Areas Going Ahead • Continuing conduct trials and studies to bring newer and effective nutritional products, which may improve the efficacy of animal feeds • Registering and introducing more products in the domestic as well as in the international markets. Animal Nutrition • Expand its sales a
Slide 30: Shareholders Information
Shareholders Information Stock Data (As on 12th May 2025) Top Institutional Holders (As on 09th May 2025) Institutions OS (%) Market Capitalization (₹) 33,178 mn ORBIMED ASIA III MAURITIUS 12.07 NALANDA INDIA EQUITY FUND 8.46 Shares Outstanding 111.88 mn ICICI PRUDENTIAL MF 3.13 CLARUS CAPITAL I 2.1
Slide 31: Thank you
Thank you Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159 Web: www.advancedenzymes.com CIN No: L24200MH1989PLC051018 Contact: Mr. Ronak Saraf Manager – Investor Relation